Has Henry Smith received payments from drug or device companies?

Yes. Drug and device makers reported $3,452 in general payments to Henry Smith across 131 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Henry Smith did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Henry Smith come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Henry Smith

Interventional Cardiology · Greensboro, NCNPI 1760582951

Payments from drug & device makers

$3,452in general payments, 2019–2025

Across 131 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$411
Abbott$321
Penumbra, Inc.$300
Abiomed$299
Novartis$253
Medtronic$212
plus $2K from 24 others

What the payments were for

Food & beverage$3,452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	23	$411
Abbott	5	$321
Penumbra, Inc.	2	$300
Abiomed	5	$299
Novartis	16	$253
Medtronic	5	$212
Irhythm Technologies, Inc.	4	$185
Johnson & Johnson	12	$153
Boehringer Ingelheim	10	$151
ZOLL Circulation Inc	1	$147
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$139
Pfizer	7	$118
Shockwave Medical, Inc	1	$104
Sanofi-aventis U.S. LLC	5	$101
Intuitive Surgical	1	$87
Chiesi USA, Inc.	4	$63
E.r. Squibb & Sons, L.L.C.	4	$52
Bayer	2	$41
AstraZeneca	3	$37
Philips North America LLC	2	$36
Daiichi Sankyo Inc.	2	$34
Boston Scientific	2	$32
Cardiovascular Systems Inc.	2	$29
Amarin Pharma, Inc.	2	$29
Esperion Therapeutics, Inc.	2	$27
Portola Pharmaceuticals, LLC	1	$23
Novo Nordisk	1	$20
Alnylam Pharmaceuticals Inc.	1	$20
Teleflex LLC	1	$14
Merck	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,452 in reported general payments places this provider in the 20th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	242	$212,275
EntrestoSacubitril/Valsartan	126	$115,131
FarxigaDapagliflozin Propanediol	126	$97,750
Repatha SureclickEvolocumab	96	$80,051
JardianceEmpagliflozin	48	$43,146
XareltoRivaroxaban	49	$40,785
DapagliflozinDapagliflozin Propanediol	18	$9,556
VascepaIcosapent Ethyl	15	$7,953
BrilintaTicagrelor	12	$5,218
NexlizetBempedoic Acid/Ezetimibe	11	$4,295
Metoprolol Succinate	217	$3,471
Rosuvastatin Calcium	195	$2,958
Atorvastatin Calcium	155	$2,009
ClopidogrelClopidogrel Bisulfate	121	$1,728
Ezetimibe	49	$1,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$118	$212,275242 claims
NovartisEntresto	$253	$115,131126 claims
AstraZenecaFarxiga, Brilinta	$37	$102,968138 claims
Boehringer IngelheimJardiance	$151	$43,14648 claims
Johnson & JohnsonXarelto	$153	$40,78549 claims
Esperion Therapeutics, Inc.Nexlizet	$27	$4,29511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Greensboro

Thomas StuckeyGreensboro$930K
Manish PatwardhanGreensboro$89K
Ravish SacharRaleigh$10.1M
George AdamsGarner$5.2M
Paul MahoneyGreenville$3.9M
Oluseun AlliCharlotte$2.3M
Patrick SimpsonPinehurst$1.6M
Matthew CavenderChapel Hill$1.5M
Rajesh SwaminathanDurham$1.4M
Steven FilbyPinehurst$1.3M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →